Open access · CC-BY
via OpenAlex
Zinc Supplementation Trial in Pediatric Chronic Kidney Disease: Effects on Circulating FGF-23 and Klotho
Vladimir Belostotsky, Stephanie A. Atkinson, Guido Filler
Canadian Journal of Kidney Health and Disease · 2024 · ▲ 5 citations
Abstract
Abstract Background Zinc status and its role in bone metabolism has not been studied in children with chronic kidney disease (CKD). Methods Forty-one children (25 male and 16 female, age 12.94±4.13 years) with CKD in native or transplanted kidneys were recruited through two pediatric nephrology divisions in Ontario, Canada and their zinc status was assessed. 14 patients (64% enrolment rate) with identified zinc deficiency received zinc citrate supplement for 3 months in the dose of 10 mg orally once a day for age 4-8 years, and 10 mg twice a day for age 9-18 years. Results Zinc deficiency (plasma concentration < 11.5 µmol/L) was found in 22 patients (53.7%). A linear regression model suggested that for every 1 unit drop of eGFR zinc concentration dropped by 0.026 µmol/L (p=0.04). Zinc deficiency was associated with higher serum intact FGF-23; however, this was predominantly determined by the falling GFR. Zinc deficient and sufficient children had similar circulating cFGF-23 and alpha-Klotho. Normalization of plasma zinc concentration was achieved in 8 patients rising from 9.96±1.48 to 12.39±3.89 μmol/L (p=0.0073). In children treated with zinc but not receiving calcitriol a statistically significant (p=0.0078) rise in c-terminal FGF-23 was observed. However, no other meaningful changes to biochemical measures or an increase in phosphaturia were observed. Conclusion Zinc status is related to kidney function and connected to bone metabolism in patients with CKD. However, it plays a minor role in fine-tuning various metabolic processes and therapeutic supplementation seems to only modestly improve bone metabolism in asymptomatic CKD patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1177/20543581241234723
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Belostotsky, V., Atkinson, S.A., & Filler, G. (2024). Zinc Supplementation Trial in Pediatric Chronic Kidney Disease: Effects on Circulating FGF-23 and Klotho. <em>Canadian Journal of Kidney Health and Disease</em>. https://doi.org/10.1177/20543581241234723
Vancouver
Belostotsky V, Atkinson SA, Filler G. Zinc Supplementation Trial in Pediatric Chronic Kidney Disease: Effects on Circulating FGF-23 and Klotho. Canadian Journal of Kidney Health and Disease. 2024. doi:10.1177/20543581241234723.
BibTeX
@article{vladimir2024ZincSu,
title = {Zinc Supplementation Trial in Pediatric Chronic Kidney Disease: Effects on Circulating FGF-23 and Klotho},
author = {Vladimir Belostotsky and Stephanie A. Atkinson and Guido Filler},
journal = {Canadian Journal of Kidney Health and Disease},
year = {2024},
doi = {10.1177/20543581241234723},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Communications Medicine 2023
Open access · CC-BY
Pregnancy-specific responses to COVID-19 revealed by high-throughput proteomics of human plasma
Nature 2019
Open access · OA
Advances in epigenetics link genetics to the environment and disease
Progress in Neurobiology 2015
Preprint · OA
The epigenetics of aging and neurodegeneration
International Journal of Molecular Sciences 2023
Open access · CC-BY
Association of Klotho with Coronary Artery Disease in Subjects with Type 2 Diabetes Mellitus and Preserved Kidney Function: A Case-Control Study
Aging Cell 2022
Open access · CC-BY
Nicotinamide riboside and caffeine partially restore diminished NAD availability but not altered energy metabolism in Alzheimer's disease
Nature Medicine 2022
Open access · OA